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A very large grey area exists between translational stem cell research and applications that comply with
the ideals of randomised control trials and good laboratory and clinical practice and what is often
referred to as snake-oil trade. We identify a discrepancy between international research and ethics
regulation and the ways in which regulatory instruments in the stem cell ﬁeld are developed in practice.
We examine this discrepancy using the notion of ‘national home-keeping’, referring to the way gov-
ernments articulate international standards and regulation with conﬂicting demands on local players at
home.
Identifying particular dimensions of regulatory tools e authority, permissions, space and acceleration
e as crucial to national home-keeping in Asia, Europe and the USA, we show how local regulation works
to enable development of the ﬁeld, notwithstanding international (i.e. principally ‘western’) regulation.
Triangulating regulation with empirical data and archival research between 2012 and 2015 has helped us
to shed light on how countries and organisations adapt and resist internationally dominant regulation
through the manipulation of regulatory tools (contingent upon country size, the state's ability to accu-
mulate resources, healthcare demands, established traditions of scientiﬁc governance, and economic and
scientiﬁc ambitions).
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).nd semi-structured interviews have been held in the following countries: China, Japan, Thailand, South Korea, Vietnam,
was done on the regulation in the USA.
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Stem cell science is a controversial ﬁeld of research with a huge
potential market for therapeutic applications on a global scale
(Department of Business Innovation and Skills (2011)). A hackneyed
view of stem cell therapy provision regards the market of life sci-
ence research and biomedical products e preparations of viable
cells, delivered through one of possible devices, such as a syringe,
and marketed commercially, requiring marketing permission in
most countries - as deeply divided between a world dominated by
advanced scientiﬁc institutions and a world of ‘rogue’ stem cell
providers (cf https://www.newscientist.com/article/dn19056-
death-revives-warnings-about-rogue-stem-cell-clinics/; http://
www.economist.com/node/15268869). The former is depicted as
ethical, sophisticated, scientiﬁcally advanced; the latter as unethi-
cal, proﬁt-motivated and uninterested in scientiﬁc advance (Sipp,
2012; McMahon and Thorsteinsdottir, 2010). But by deﬁning the
difference in moral terms, critics do not do justice to the efforts of
many researchers involved in stem cell therapy research and pro-
vision, for example, in Asia. In fact, we can discern only a few
players that can afford to conduct clinical trials in tightly regulated
research ﬁelds in ways that match the ideals of the dominant in-
ternational science community, and only a few corrupt so-called
‘snake-oil providers’ (Sleeboom-Faulkner, 2014). Instead, a very
large grey area of stem cell-related activities exists in which stem
cell scientists, doctors, politicians and regulators accommodate,
adjust, circumvent and alter regulatory spaces to help advance
clinical research in ways that suits their circumstances.
The current use of the binary between bona ﬁde science and
snake oil traders has its roots in a situation in which a few inter-
national organisations and countries driven bymembers fromwell-
funded, cautious research laboratories set the standards. Those that
do not stick to agreed conventions are seen as undisciplined and
fraudulent (Sipp, 2012; Bharadwaj and Glasner, 2008). This binary
has led to the tainting of a large group of under-resourced re-
searchers, and to one-sided portrayals of their aims. Scientists
delineate themselves from the ‘science’ of other scientists, claiming
scientiﬁc integrity for themselves. Although this ‘boundary work’ is
inherent to the scientiﬁc community (Gieryn, 1983; Gilbert and
Mulkay, 1984; Salter and Qiu, 2009), it is now played out on a
global level, expressed in papers on ‘research ethics’ and ‘good
practice’ at international scientiﬁc conferences.
Recent years have seen a new regime of coordination of medical
practices linking medicine and biology together that has led to the
increased articulation of genomic biology, multicentre clinical tri-
als, organised patient communities, and biobanks, which depend
on sophisticated laboratories, reliable instruments and devices that
produce exchangeable results. Standard setting, guidelines and
regulation are central to this regime. Thus ‘regulatory objectivity’
(Cambrosio, Keating, Schlich an&d Weisz, 2006) deﬁnes the con-
tents of what the dominant science community regard as correct
practices (Birch, 2012). These standards are often conventions:
what counts here is that results are compatible with other labo-
ratories, whereby ‘truth’ and ‘accuracy’ become dependent on these
conventions. In regenerative medicine (RM), referring to research
and therapies using the regenerative powers of the body, the In-
ternational Stem Cell Initiative (ISCI), for example, has taken the
initiative to deﬁne pluripotency and assays, and the media and
reagents used to produce them (Eriksson and Webster, 2008).
Standards do not only facilitate exchange, they can also deﬁne the
clinical criteria in terms of diagnosis. Thus, scientiﬁc standards and
assays for mesenchymal stem cells are critical both to the
advancement of scientiﬁc development and clinical practice
(Bianco et al., 2013). Crucially, the exchangeability and common use
of data require the deployment of similar equipment, devices andassays. This has major economic and intellectual property rights
(IPR) implications to the advantage of those that set the standards,
and to the disadvantage of the reputation of researchers that
cannot comply with them (PRNewswire, 2014; Birch, 2012).
These developments pressurise scientists all over the world to
follow the standards of elite laboratories. At the elite levels, scientiﬁc
knowledge is sanctioned by international peer-reviewed journals,
regulation vetted by expert committees in modern bureaucracies,
and novelty deﬁned by IPR. Here, political discourses on norms and
values deﬁne the ethics acceptable to a small number of societies
(Timmermans and Epstein, 2010; Birch, 2012). International collab-
oration, then, requires elite laboratories inmost countries, including
thosewith fewresources, todemand regulations thatenforce ‘global’
standards. But the necessity to purchase costly equipment and re-
sources has also led to resistance against regulatory norms and
standards by those less well endowed (Sleeboom-Faulkner, 2013).
Insight into this friction between compliance and resistance is
complicated by an ever-increasing demand on scientiﬁc leaders to
be familiar with research regulation and research ethics, multiple
scientiﬁc ﬁelds, IPR, methods of team management and business
strategies, leading to development of ‘bioenterpreneurship’, ‘bio-
networking’, and ‘international entrepreneurship in the life sci-
ences’ (Jones et al., 2011: 2; Sleeboom-Faulkner and Patra, 2011)
engaging with coordinative activities and methods using local
knowledge resources and international connections. Here, values
and methods are constantly weighed to realise the desired kind of
‘local’ model of scientiﬁc decision-making, considering, for
example: the cost, feasibility and aptness of the ‘right’ number of
patients used in investigational studies or clinical trials; the quality
of preclinical studies and toxicity studies; the fees charged for
investigational studies using unauthorised stem cell products; and
the ways of marketing therapy products. Global variability of
therapy marketing and patient demand complicates the picture of
compliance and resistance even further (Petryna, 2009; Chen and
Gottweis, 2011). This variability has resulted in a situation in
which the relationship between patients and doctors is conditioned
by availability of research funding, expertise and medical facilities,
as well as collaborative networks and regulatory constraints.1.1. National home-keeping
At the intersection of the international and local governance of
stemcell science,we locatea formofdecision-making,whichwerefer
to as ‘national home-keeping’. National home-keeping is a heuristic
notion we use to capture policies designed when countries face uni-
versal standards, often created ‘elsewhere’, that are not conducive to
local policies of economic, health and scientiﬁc development. In this
article,we illustratehowpolicies ofnationalhome-keepingcondition
stem cell innovation through regulation and regulatory instruments.
This article follows global assemblage approaches (Ong and
Collier, 2005; Sleeboom-Faulkner, 2014) that avoid assuming an
encompassing global force or a pre-existing local path, but inves-
tigate the dynamic interactions among international, regional, and
local politics. Although various works in particular on human em-
bryonic stem cell research have appeared in a global setting
(Thompson, 2013; Gottweis et al., 2009; Webster, 2013; Zhang,
2012; Bharadwaj and Glassner, 2008; Sleeboom-Faulkner, 2014),
issues discussed in theseworks regard the status of the embryo and
gamete donation rather than issues of clinical applications.1
2 The law on therapeutic cloning (Sleeboom-Faulkner, 2011a) and the 2013
regulation for cell therapy (see below) are seen as exceptions.
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tance of analysing RM in the context of globalisation, global politics
and global governance (Thompson, 2013; Gottweis et al., 2009).
These and other works (Salter and Qiu, 2009; Salter et al., 2015;
Thompson, 2013; Bharadwaj and Glasner, 2008) have especially
focused on the central role of bioethics in the brain drain and global
dynamics of stem cell science. Some (Salter et al., 2015; Cooper,
2008) have emphasised the centrality of global competition and
hegemony in the global dynamics of stem cell development,
whereby bioethics and stem cell governance has become a pawn in
a global race. This article, however, emphasises the importance of
the dynamic interaction of global regulatory changes between and
within countries, including radical regulatory changes in Japan and
South Korea, regulatory crises in China and India, gradual reform in
the EU and the USA. These, we argue, derive from policies that aim
to enable scientiﬁc innovation at home, and are intimately linked to
the emergence of new international movements.
Our views differ from other works discussing translational RM
in a global context, as it is more comprehensive and systematic in
pointing out, not so much the inﬂuence of political cultures of
governance, but the speciﬁc circumstances of different countries
that variously condition the adoption of particular regulatory
policies. Rather than taking the political and bioethical cultures of
nation-states as following global powers, this article uses the
notion of ‘national home-keeping’ as a heuristic tool to analyse the
ways countries deal differently with the standardisation of
research. Rather than accommodating what are regarded as bona
ﬁde global guidelines, national home-keeping policies articulate
international regulatory trends with home conditions comprising
competing local views and interests to enable innovative research
applications. As a result of both regulatory diversity and dissat-
isfaction with national home-keeping policies, we argue, scien-
tists have organized themselves in networks that recommend
different sets of regulatory guidelines both at home and in a global
context.
1.2. Methodology and conceptual overview
Our research on translational stem cell applications builds on
over three years of research across Asia, Europe and the US, using
both local languages and English to communicate with in-
terviewees and read written resources. The research set out to
examine different local and regional translational stem cell
research practices. Interviews with regulators, scientists, medical
professionals show that modes of regulation and ISSCR guidelines
play a central role as main reference points in understandings of
translational stem cell research. Discussing differences in inter-
national regulation and local translational science, interviewees
consistently referred to regulatory dimensions of authority, per-
missions, regulatory space, acceleration of regulatory pathways
and implementation as main research issues and factors. Our
research has found a link between the national development of
regulatory tools mobilized in home-keeping policies and the na-
tional conditions they build on, which we correlate with policies
aimed to enable local development of the ﬁeld. We discuss ex-
amples of locally mobilised tools in Part II, with the exception of
‘implementation’. We analyse ‘implementation’ in Part III together
with the pattern we delineated in home-keeping policies of the
countries examined. This pattern is based on the kind of regula-
tory policies over six years (2008e2014): adjustment, radical
change, impasse and early formulation of regulation (see Table 1).
The identiﬁcation of this pattern, in turn, led us to analyse the
similarities and difference between countries with divergent
home-keeping policies, the results of which we outline in Part III.
Part IV discusses how, as a result of the existent diversity ofregulation and dissatisfaction with national home-keeping policies
organisations and networks have emerged that champion very
diverse international guidelines and standards. We discuss their
activities, questioning the designation of ‘international’ in this
context.
Field methods used include semi-structured interviews and/or
archival research carried out by the authors across Asia and in the
UK between 2011 and 2015. The materials presented draw on in-
terviews with regulators, company managers, scientists, medical
professionals and patients (see Appendix) and six workshops on
translational stem cell applications and patient needs in London,
Brighton, Seoul, Beijing, Bangalore and New Delhi. Interviews were
analysed by repeated readings, thematic content analysis, identi-
ﬁcation of signiﬁcant examples, and the abductive method
(Timmermans and Tavory, 2012) for exploring the ‘home-keeping’
concept. One co-author was a member of the UK's government-
advising Regenerative Medicine Expert Group (RMEG) during
2014 and attended European Medicines Agency Committee for
Advanced Therapies Interested Parties meetings, both further data
sources. The data presented are anonymised and the names of in-
terviewees are pseudonyms. All interviewees cited in this article
have been informed of the research and have consented to be
interviewed for this study. The research was approved by the ethics
committee of the University of Sussex and King's College London.
2. National home-keeping and regulatory policy-making
National home-keeping policies direct the development of sci-
ence to articulate international regulatory trends with socio-
political and economic policies and home conditions. De-
velopments in cell therapies are subject to changes in science
policies, science funding and science regulation The effectiveness
and reach of science regulation, however, can be steered in many
ways, for example, by assigning a particular level of authority to
regulation, through funding-linked incentives, such as research
review, scientiﬁc protocols and research ethics, and through per-
missions, such as for investigational studies/trials, experimental
research spaces for research involving human subjects and mar-
keting licenses. In this section, we discuss how innovation for stem
cell therapies in particular is conditioned through regulation in Asia
and in EU and the USA. Apart from in the ﬁrst subsection, we focus
on the EU and USA to indicate the variability in regulatory pro-
visions in the part of the world often associated with advanced
science and technology. It also serves as a reference in discussing
national home-keeping in Asia in Part III. The section sketches the
variety and ﬂexibilities of the regulatory landscape in terms of
authority, permission, space and acceleration, embodied in policies
of ‘national home-keeping’.
2.1. Regulatory authority
National home-keeping policies can condition regulatory tools.
Thus, countries might diversely regulate the development of stem
cell applications by legal means (hard law), formally sanctioning
violation, or through guidelines, that is, soft law. Some countries,
such as Japan, until recently, have predominantly used soft law,
which can be very effective when social/institutional controls are
available at the ground level (Ida, 2002).2 Other countries make use
of a range of regulatory levels with varying degrees of authority. For
instance, China has laws (法), administrative regulations (行政法规),
departmental regulation (部门规章), ethical principles (伦理原则)
Table 1
Pattern of regulatory policy-making.
Traditionally scientiﬁc leaders Large LMICs Scientiﬁcally advanced Asian countries Small LMICs
Regulatory adjustment US/EU
Sustained regulatory impasse India/China
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2013). New regulation usually comes out as draft (草案) or trial
regulation (試行), amenable to change. In addition police and
armed forces have their own regulation for scientiﬁc research and
medical treatment in hospitals and research centres.
In Europe and the USA we see major differences in the orga-
nisation of regulations and the status assigned to different forms,
with traditionally a relatively high reliance on soft law in Anglo-
American countries compared to continental Europe. For
example, the UK is well known to have a highly regulated system
but liberal laws for stem cell research, while France is the oppo-
site. Furthermore, national authorities implement the European
Medicines Agency (EMA) regulations through varying national
regulatory and/or legal mechanisms. In the USA, the Food and
Drug Administration (FDA) regulates translational stem cell
research federally, but leaves powers to the private sector and
state governments. Finally, the status and authority of regulatory
organs are subject to constant innovation, as will become clear
below. The political and legal status of regulation is crucial in
understanding its impact.3 See http://www.wma.net/en/30publications/10policies/b3/.
4 Compiled by the main author with assistance of the co-authors. The ﬁgure was
empowered by Gliffy software embossed onto ‘outline-world-map’ (www.outline-
world-map.com).2.2. Permissions for investigational studies e geographic
dimensions
Innovative stem cell treatment in most countries requires
permission from a local institutional review board (IRB) or equiv-
alent and from a higher-tier organisation at provincial or national
level. Nevertheless, speciﬁc requirements can differ substantially
per country. Scientists who are aware of this can decide to collab-
orate strategically (Sleeboom-Faulkner and Patra, 2011) to enjoy
advantageous regulatory conditions. This might require collabora-
tive partners to comply with international guidelines, including
Good Laboratory Practice (GLP), Good Manufacturing Practice
(GMP), and ethics review. In some countries, local conditions for
permission for clinical studies clash with national science policies,
whereby the former encourages and the latter curtails clinical ap-
plications. For instance, the Guangzhou municipal government in
southern China had funded translational stem cell applications
discouraged by the national government (Interview X, 25-4-13/
Guangzhou; P, 28-4-13/Guangzhou).
In some countries, national permission for the clinical applica-
tion of stem cell products may only be necessary for marketization.
This means that hospitals can provide treatment using unau-
thorised stem cell products as long as they do not charge for the
stem cell products; they charge for the ‘service’. Alternatively, stem
cell products are applied off-label for indications without evidence
for their safety and efﬁcacy. Suchmethods enable clinics in the USA,
China and India to continue to provide treatments that have not
been recognised at home (Richer, 2011). In the USA permission can
be acquired to take an experimental drug across state boundaries.
Thus, through the Investigational New Drug (IND) programme in
the USA, a pharmaceutical company can obtain FDA permission to
ship an experimental drug across states (usually to clinical in-
vestigators) before an application for marketing a drug has beenapproved (US FDA, 2014a). This possibility opens up a large pool of
potential subjects for clinical trials.
2.3. Creating spaces for procurement of innovative treatment and
experimentation
Apart from following the pathway of clinical trials, there are
other ways of making innovative treatments available. One is
compassionate treatment, a term usually referring to a last-resort
treatment for individuals without other options, also used by re-
searchers who do not have permission for clinical trials. Thus, the
Indian company Neurogen justiﬁes stem cell therapy provision for
Duchenne muscular dystrophy (DMD) and other conditions by
appealing to compassionate use as cited in section 37 of the World
Medical Association Declaration of Helsinki on Ethical Principles for
Medical Research Involving Human Subjects,3 which states that
doctors may use experimental therapies when no other treatment
is available (Sharma et al., 2014: 236). The US FDA allows only a very
few cases of compassionate treatment exemption, as researchers
can charge patients (Cyranoski, 2011), while the EU regulates
compassionate treatment separately from research.
The EU's Advanced Therapy Medicinal Products (ATMP) Regu-
lation (Article 2[2]) provides the Hospital Exemption (HE) clause,
which allows member states to facilitate ‘non-routine use’ for in-
dividual patients in the absence of a marketing authorisation
(European Commission, 2014). The uneven implementation of the
HE due to different interpretations in European countries, however,
has led to a broad use of the clause, and it is feared that it deters
users from applying for market authorisation for ATMP. For
instance, while TiGenix developed cartilage treatment by going
through the central regulations, others used the HE for similar
treatment indications (House of Lords (2013): 544). The pre-
existing UK's ‘Specials scheme’, which is covered by Article 5(1)
of Directive 2001/83/EC, allows for the manufacturing and provi-
sion, including import, of unlicensedmedicines for the treatment of
rare disease and the use of drugs for individual patients' unmet
needs (Lowdell et al., 2012; Mahalatchimy et al., 2012). It can be
scaled up and used across Europe, with themanufacturer paying for
the process rather than the product (MHRA, 2007; European
Commission, 2014).
Applications can receive extra incentives in terms of fees and
priority at any stage of the development of therapeutic products
through the Orphan Drug Designation (ODD) if certain ‘rare disease’
criteria are met. For instance, Multi-Stem, a US-based company,
which created a graft versus host disease (GvHD) prophylaxis for
leukaemia patients receiving allogeneic (from others) haemapoeitic
stem cells (HSCs), has received ODD both from the FDA and EMA for
its allogeneic multipotent adult progenitor cell based ‘MultiStem
therapy’ (Athersys Inc., 2013).
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In the EU, some stemcell productsmaybe used clinicallywithout
marketing licence. This, however, does not mean that they are un-
controlled, as is illustrated by the ODD, HE and Specials, pathways,
which essentially assign spaces of development. In addition, accel-
erated licensing routes are possible under certain conditions. In
2012, the US Congress passed the FDA Safety Innovations Act
(FDASIA). Section 901 of FDASIA amends the Federal Food, Drug, and
Cosmetic Act (FD&C Act) to allow the FDA to accelerated approval
for drugs for serious conditions that ﬁll an unmet medical need,
using a surrogate or an intermediate clinical endpoint (also see, US
FDA, 2014c). Post-marketing conﬁrmatory trials are generally
required to verify and describe the anticipated clinical beneﬁt or
effect (US FDA, 2014b). In the EU, the European Medicines Agency
(EMA) has integrated a number of initiatives, including adaptive
trial design, named the Medicines Adaptive Pathways to Patients
(MAPPs) programme, aiming to create an approval process that
adapts quickly to a givenpatient's response to therapies, focusing on
clearly deﬁned patient populations with unmet medical needs
(EMA, 2014; Forda et al., 2013). However, no agreement exists yet
aboutminimal standards of scientiﬁc evidence and reimbursement,
and these initiatives do not sit within EU pharmaceutical or other
law. In the same vein, in the UK the MHRA has piloted the Early
Access to Medicine Scheme (MHRA, 2014) ‘to support access to
unlicensed or off-labelmedicines in areas of unmetmedical need’. It
uses a Promising Innovative Medicine (PIM) designation, similar to
the Breakthrough Therapy designation in the USA, and will involve
collaboration between existing institutions, such as the National
Institute for Health and Care Excellence (NICE) and the National
Health Service (NHS) (MHRA, 2014). The data requirements for a
PIM are less than those for a formalmarketing application dossier. A
more fundamental approach to market acceleration took place
earlier in South Korea and Japan, where Biologics License Applica-
tions (BLAs) are conditionally provided for new investigational
drugs after producing evidence of safety and plausibility of efﬁcacy
(see below). Researchers in the USA and in Europe, on the one hand,
are concerned about the consequence of using ‘deviant’ standards
and regulatory norms and, on the other hand, worry that they are
losing a competitive edge (Freeman and Swidlicki, 2014).
To summarise, overall we can see a wide variety of ways in
which different countries, notably the US and EU, have been
introducing a range of different, limited, ﬂexible measures, some
hard law some soft, some within legal regimes some extra-legal,
designed to enable the authorisation and mandating of innova-
tive stem cell (and other cell) technologies, while maintaining their
core commitment to traditional biomedical standards and meth-
odologies and their related regulatory and institutional cultures
which support highly innovative bioeconomic stem cell science
entrepreneurship.
3. Patterns in national home-keeping
Our comparison of the performance of national home-keeping
policies across countries has enabled us to identify correlations
between regulatory policies and the situational conditions of
countries in a global context. The intentions behind regulation can
be difﬁcult to verify. We therefore need to gauge its political
meaning from the context of overall trends in scientiﬁc in-
frastructures and institutional cultures in countries to improve our
understanding of regulation performance (Sleeboom-Faulkner,
2011b; Faulkner, 2012) in particular political contexts.
Local regulation takes into account infrastructural factors such
as the supply of working electricity, affordable reagents, training for
technicians, public communication channels, and a modernadministration. In India, the absence of a responsive bureaucracy
has frustrated scientists who have applied for National Apex
Committee (NAC) permission to conduct clinical trials (interview, B,
06/08/2013-India; personal communication G, 11/11/14-UK). In
many countries, applying for permission for clinical trials is left to
the individual institution. In India, an ofﬁcial from the Indian
Council for Medical Research (ICMR) said that audits might never
reach those institutions that have not applied for permission
(interview N, 18/09/2012-IN).
A shared scientiﬁc culture is needed to indicate what is accept-
able in stem cell product applications. But in China and India in-
terviews show that sharp conﬂicts developed between local funders
of stem cell product applications and the national government over
the conditions under which they may be used and marketed. In
Thailand, Japan, South Korea and Taiwan, we regularly found stem
cell products on offer as cosmetic cell therapy or as holistic medi-
cine. Disagreement about the interpretation of key terms can un-
dermine effective regulation. One example is the meaning of
‘minimal manipulation’ of stem cells. In the USA the companies
RNL/Celltex and the FDA disputed whether the expansion of stem
cells constitutes minimal manipulation, falling under the medical
practice law (regulated by Texas), or whether it should be treated as
a biological drug, regulated by the FDA (Cyranoski, 2013a). Another
example is the contentious interpretation of the ‘non-routine’ use of
stem cell products for individual patients authorised through the EU
Hospital Exemption (EBE, 2011). A last example from Thailand re-
lates to the term ‘stem cell therapy’, whereby the notion of ‘stem
cell’ indicates that it requires state authorisation. To avoid criticism,
companies advertise the application of unauthorised stem cell
products as ‘cell treatment’ (Chaisinthop, 2014).
The 2013 overview of stem cell and genetic engineering prod-
ucts withmarketing permission in Fig. 1 gives a general idea of how
countries make regulation work for innovation in RM. As will
become clear below, this ﬁgure does not represent so much the
scientiﬁc advancement or productivity in RM of a country, as it does
the kind of regulatory policies it has adopted.
3.1. Wealthy, traditional leaders of scientiﬁc development and
regulation
Until recently, the USA and EU have insisted on following sci-
entiﬁc regulation for developing stem cell technology based on the
traditional preclinical testing and clinical trial model, although as
described above this translational paradigm itself is increasingly
open to various, limited ﬂexibilities. While clamping down on
therapies using unauthorised stem cell products regulatory spaces
have been created for promising stem cell technologies. Some of
these regulatory spaces are of a local nature, and entail the high
costs, bureaucracy and time needed for the pathway of randomised
control trials (RCTs), as well as investigational research using a
small number of available human subjects. The following sub-
sections discuss initiatives that organise and standardise stem cell
research in Asia, contra the US/EU cases, whose regulation we have
characterised above as adjusting incrementally.
3.2. Large and scientiﬁcally ambitious low- and middle-income
countries (LMICs) (India, China)
Large and scientiﬁcally ambitious LMICs, such as India and
China, pool resources to develop a life science industry, though they
can afford only a limited number of high-tech laboratories per head
of the population. Inﬂuential commercial actors play a leading role
(e.g. Stempeutics and Reliance in India; Beike Biotech and Zhon-
gyuan Union Stem Cell Bio-engineering Corporation in China).
Apart fromwell-equipped commercial actors, both countries have a
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skills and collaborations. Stem cell therapy enterprises linked to
hospitals are readily found on the Internet. In both countries local
and national governments invest heavily in the life science in-
dustry, and a call exists for an ‘ethics of return’ in the form of
beneﬁts to patients. In this context, stem cell researchers are put
under pressure not only to develop the ‘world's highest-standard
medicine’, but also the ‘world's ﬁrst clinical applications'. Scien-
tists in India and China express concerns about the recognition of
their work, which are heightened as local scientists see that clinical
experiments they started years ago are now part of clinical trials
elsewhere without recognition of their contribution. This creates a
dilemma for scientists and policy-makers (interviews X, 28/04/
2012-China; H, 12/11/14_UK).
3.3. Small LMICs (Thailand, Malaysia, Vietnam)
Small LMICs invest relatively little into infrastructural develop-
ment and translational stemcell applications and have no concerted
policy directing the research (Perez Velasco, Chaikledkaeew, Myint,
Khampang, Tantivess and Teerawattananon, 2013; Saengpassa and
Sarnsamak, 2012). For example, although Malaysia since 2005 has
invested RM 3.2 billion in 225 so-called BioNexus-status companies
through its Malaysian Biotech Corporation (Bionexus, 2014), its
ﬁnancial capacity into national stem cell science is clearly inferior to
that of India and China.
Although regulation for local approval by an IRB and the na-
tional authorities in Thailand, Malaysia and Vietnam is in place
(MoH Malaysia, 2013; TMC, 2009,5 NIHBT, 2011), presumptions of5 Non-compliance may lead to the revocation of medical license (Medical Pro-
fessional Act B.E.2525 (1982) Section 21 (3).‘loose regulation’ make these countries targets for collaboration.
Examples include the University of Texas MD Cancer Anderson
Centre supporting clinical trials with bone marrow transplants in
Bangkok (Bionews Texas, 2013); Japan and India's joint-venture
Niscell, which provides autologous (from self) stem cell therapy
and conducts clinical stem cell trials inMalaysia (Niscell, 2013); and
India's Stempeutics' clinical stem cell trials in Malaysia
(Stempeutics, 2013; Bionexus, 2014). Regulation of translational
stem cell applications in these host countries tends to be brief and
general, so that the conditions under which authorised clinical
trials take place are unclear (TMC, 2009; MOH Malaysia, 2013;
Thomson Reuters, 2015).
In Thailand and Malaysia, scientists and medical professionals
expressed worry about the country's scientiﬁc reputation. Some
clinics offer ‘stem cell therapies’ commercially, such as those
attached to Beike Biotech and Wu Medical Centre,6 while others,
such as TheraVitae, and SiriCell, have closed down. Even when
regulation prescribes the application for permission from a Na-
tional Ethics Committee, clinics offer treatment using stem cell
products commercially without. Examples are Cellport, VillaMed-
ica, PatrLife, AbsoluteHealth, HolisticMedical Centre in Thailand7;
StemCellMalaysia, StemLife, and WhatClinic in Malaysia.8 In Viet-
nam, a late-developer in this ﬁeld, hospitals offer commercial
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RNL (renamed K-Stemcell), Asian Stem Cells, and KenCare.9 In all
three countries scientists and regulators worry that investment in
RM does not serve the interests of the majority of patients
(Saengpassa and Sarnsamak, 2012), who cannot afford the treat-
ments on offer in the private sector.10 http://www.stemcellconsortium.org/uploads/documents/Montreal_White_3.4. Scientiﬁcally advanced and ambitious medium-sized countries
in Asia (South Korea, Japan)
Two scientiﬁcally advanced countries in Asia, South Korea and
Japan, have reorganised their regulation to speed up the process of
translational research by means of fast-track pathways for certain
kinds of stem cell applications. To uphold safety, a complex form of
implementable regulation has been devised, including standards
for ethics, GMP/GLP, banking, permissions, market licensing, and
follow-up treatment. South Korea's Regulation on the Review and
Authorization of Biological Products introduced ‘fast-track
approval’ (KFDA, 2010; MFDS, 2013). Thus, the Korean Food and
Drugs Administration (KFDA) has eased its regulation on the use of
autologous cell products over the last few years by granting
exemption from submission requirements and exemption from
phase I trial when the data have been published in professional
journals (Notiﬁcation 2011-225, 2011). Furthermore, the MFDS
(which replaced the KFDA in 2013) allows post-marketing sub-
mission of documents concerning the efﬁcacy for medicinal prod-
ucts for serious and life-threatening diseases, including AIDS and
cancers, and when there is no other treatment option available
(MFDS notiﬁcation 2013-238, article 58). Not surprisingly, South
Korea has been the ﬁrst in approving stem cell products: Heart-
icellgram and Cartistem for Osteoarthritis and Cupistem for Crohn's
ﬁstula (Wohn, 2012), followed by many others (see Fig. 1).
Having been frustrated by its slow regulatory bureaucracy, and
hoping to take induced pluripotent stem cells (iPS) to the clinic ﬁrst,
Japanese regulators and scientists conﬁrmed that they looked to
South Korean regulatory efforts to revise Japan's. In 2010, the Jap-
anese government revised ‘the guideline for clinical studies using
human stem cells’, expanded its coverage to clinical studies using
embryonic stem cells and induced pluripotent stem (iPS) cells. In
2013, three new (hard) lawswere introduced, of which the ﬁrst, the
Regenerative Medicine Promotion Act, was enacted in May 2013. It
promises to promote RM among the Japanese population, linking
state efforts with industry, and devising policies in support of
bringing RM to the clinic. The second, The Act on the Safety of
Regenerative Medicines, was enacted on 25 November 2014, and
uses a three-tiered system based on risk-assessment to determine
the level of required research oversight. In cases of high risk
(involving pluripotent cells) and medium risk (involving somatic
stem cells), medical institutions need to apply for permission from
a special committee for RM identiﬁed by the Ministry of Health,
Labour and Welfare (MHLW). The third, the Revision of the Phar-
maceutical Affaires Law: The Pharmaceuticals, Medical Devices,
and Other Therapeutic Products Act (PMD. Act), enacted on 25
November 2014, stipulates that the Pharmaceuticals and Medical
Devices Agency (PMDA) and the MHLW provides an expedited
approval system for regenerative medical products. After the safety
is conﬁrmed and the results predict likely efﬁcacy, the product will
be given conditional, time-limited marketing authorisation (PMDA,
2014; Azuma, 2015). This radical regulatory reform, allowing9 http://english.vietnamnet.vn/fms/science-it/71113/growing-stem-cells—a-new-
proﬁtable-business-in-vietnam.html; http://www.unistemcells.com/en/
patientstory/Parkinson7614015300.htm; http://www.asianstemcells.com/; http://
corporate.kencare.com.sg/home/english/news/Ms-Nguyen-Thi-Ngoc-Anh.164.html.market authorisation before the provision of scientiﬁc evidence
through clinical trial (Cyranoski, 2013b; Nikkei, 2014), has already
attracted the interest of large companies, such as Athersys, Meso-
blast, and Cytori Therapeutics (Market Watch, 2014). Also, com-
panies from elsewhere in Asia, such as India's Stempeutics,
consider approaching Japanese partners (interview J, 23/09/13-
India). Nevertheless, considering the fear of scandal from the side
of regulators, and the uncertainties around post-marketing condi-
tions of cell products (interview K, 1/11/13, Japan), it might take
some time before new stem cell products will be given marketing
permission.
In short, our examination of the ways in which countries un-
dertake boundary-work to harness the regulation of RM in an in-
ternational context led us to categorise countries according to their
size, the state's ability to accumulate resources, healthcare de-
mands, established traditions of scientiﬁc governance, and eco-
nomic and scientiﬁc ambitions (see Table 2).
As we have discussed, the traditional leaders in the ﬁeld in the
EU and USA have been adjusting their regulation to the demands of
RM in piecemeal fashion. The ability of large LMICs to pool re-
sources allows them to catch up with elite laboratories, but
simultaneously these countries face regulatory difﬁculties in
dealing with the needs of under-resourced players, which found
other investors through local and international collaborations, and
compete in the international stem cell therapy and bankingmarket.
Small LMICs entering the stem cell science scene only gradually
develop their scientiﬁc and regulatory capacity, mainly by focusing
on and protecting a few pioneering institutions, while opening up
the country to foreign investors. In scientiﬁcally ambitious and
advanced medium-sized countries the regulation of RM has
changed radically, and no longer requires strict criteria before
marketing. This change is pushed by the desire to see investment
yield clinical applications rapidly, and pulled by the competition
faced by countries that hitherto have traditionally deﬁned the
conditions of innovation in RM.4. International stem cell organisations and networks
Regulatory diversity regarding translational stem cell science
has led to initiatives aimed to harmonise international regulation
and standards. They not only facilitate exchanges in scientiﬁc
knowledge, but also funnel and discipline their membership by
stipulating ethical review, scientiﬁc protocols and common scien-
tiﬁc standards. Examples of such organisations are the Alliance for
Harmonisation of Cellular Therapy Accreditation (AHCTA), the In-
ternational Consortium of Stem Cell Networks (ICSCN, 2004,
Montreal),10 the International Society for Stem Cell Research
(ISSCR), the International Society for Cellular Therapy (ISCT, 1992),
the International Stem Cell Forum (ISCF),11 and the International
Stem Cell Initiative (ISCI, afﬁliated to the ISCF). Regional networks,
such as the Stem Cell Network (Canada), Eurostemcell and Stem cell
Network Asia Paciﬁc (SNAP, 2007) also encourage standardisation,
collective policy-making and collaboration.12 Initiatives focusing on
biobanking, such as the International Stem Cell Registry (ISCR),13
the European hESCreg,14 the European bank for iPS cells (EBiSC,







Factors underpinning national home-keeping policies.
Large country size and centralised accumulation of
resources
Enable large-scale investment scientiﬁc ﬁelds, but facilitates regional diversity and hinders regulatory
implementation
Established traditions of governing RM Institutional stickiness can hinder radical change
High healthcare demand High demand for treatment as push factor of scientiﬁc application
RM as economic growth tool Encourages regulation that allows competitive applications
Position in the international science community Scientiﬁcally advanced and independent research communities can afford to develop their own regulatory style
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tional scientiﬁc standards and restrictive national home-keeping
policies, a number of initiatives aim to legitimise stem cell treat-
ments with high patient demands that have not been recognised by
international stem cell institutions. These initiatives are charac-
terised by different degrees of size, ranging from global to local. We
here discuss some initiatives from Asia, which are not necessarily
representative of all those diverging from the dominant stem cell
regimes described above.
The International Cellular Medicine Society (ICMS, Salem, Ore-
gon) has 3500 physicians and patients in 35 countries with chap-
ters in China, Peru, Mexico, Argentina and Venezuela. ICMS
developed its own guidelines,17 an IRB, and an international
physician and patient network, and it forged collaboration with
AABB (American Association of Blood Banks).,18,19 The ICMS
announced a framework for the clinical translation of cell-based
therapies, focusing on establishing standards and guidelines for
studies that fall outside the jurisdiction of the FDA. However, after
acrimonious debate and an FDA audit in 2012, ICMS had to close its
IRB.20 Nevertheless, the AABB Center for Cellular Therapies con-
tinues to be highly inﬂuential as an accreditor,21 a service used by
companies in Thailand, China and India to advertise their interna-
tional reputation.22
The China SCI-Net, largely funded by a Hong Kong charity and
linked to SCI USA, involves a transnational collaboration that aims
to bridge efforts across diverging regulatory requirements, scien-
tiﬁc practices, and interests. China SCI-Net aims to ﬁnd spinal cord
injury treatment using lithium and cord blood cells in a fast and
safe way, involving more than 20 leading clinical centres in Main-
land China, Hong Kong and Taiwan. It conducts trials through local
hospitals whose staff were trained to follow the Net's own proto-
col.23 The conﬁguration of international skills, training, patient
network, funding and local regulation has its own dynamics
through which it develops standards that chime with the national
situations it works in (Rosemann, 2014).
The International Association of Neurorestoratology (IANR), set
up in 2004 in China, is a broad professional platform of academic
exchange for scientiﬁc researchers and clinicians from over 30
countries working in the neurorestoratological ﬁeld, including
neurology, orthopaedics, rehabilitation, cell transplantation, Chi-
nese traditional medicine and psychiatry. It develops its own pro-
tocols for conducting clinical trials to evaluate the safety and efﬁcacy





20 Knoepﬂer Lab Stem Cell Blog, posted on 10 May 2014: http://www.ipscell.com/
tag/international-cellular-medicine-society/.
21 http://www.aabb.org/aabbcct/Pages/default.aspx.
22 For instance, Jiangsu Beike Bio-Technology Co., Ltd; Lifecell International Pvt.
Ltd., Chennai prominently advertise their AABB accreditation for somatic cell
facilities.
23 http://www.chinascinet.org/index.php?option¼com_
content&task¼view&id¼23&Itemid¼53.outcome measures, and ethical treatment of patients.24 IANR uses
its own form of ‘self-assessment’ as one of the criteria for success.25
The Guangzhou Stem Cell and Regenerative Medicine Alliance
includes 18 research institutes, hospitals and companies in
Guangzhou Province, and aims to further basic stem cell science,
share resources and to develop translational stem cell research
activities and applications.26 A scientist related how the Alliance
established its own rules for the clinical translation of stem cell
products to respond to patient demands and local investors, but
was forced to ceased treatment provision.27
The Cellular Biomedicine Group Inc. (CBMG) of Shanghai, which
has recently reported on the completion of a phase II stem cell trial
for knee osteoarthritis (KOA), claimed to follow ‘international’
standards.28 Since the government has prohibited treatments using
unauthorised stem cell products, ‘regulatory uncertainty’ led CBMG
to apply for marketing permission of the autologous stem cells
undermedical device regulation. Although this is a quickmethod of
acquiring permission, it is limited to the hospital in which it is
obtained. For this reason, a company will typically conduct multi-
centre trials for a disease in a group of hospitals, and if it proves safe
and efﬁcacious, receive permission to sell in these hospitals.
The exempliﬁed organisations illustrate the existence of inter-
national organisations with contrasting aims. They look to inter-
national and local allies for support of their research methods and
standards and seek shelter under the protective umbrellas of in-
ternational professional communities and local business commu-
nities. But the roots and targets of these movements lie mainly in
the national home-keeping policies that articulate international
regulatory trends with workable rules for regulation, funding, in-
frastructures, and treatment on a national level.
5. Conclusion
As we have demonstrated, national home-keeping policies use
regulation to enable translational stem cell applications despite the
existence of international authorities such as the ISSCR. As a heu-
ristic tool, the concept calls for attention to how countries formu-
late stem cell policies through locally available political and
regulatory mechanisms to articulate circumstances at home with
global regulatory trends: governments can alter the status of na-
tional and local regulation; use various kinds of permissions for
stem cell studies, trials, and provision; create regulatory clauses to
make spaces for experimentation; allow hidden deployment of
unauthorised therapies, and accelerate pathways to the marketing
of stem cell products. The implementation, understanding and use
of regulation are modulated by variable infrastructures and insti-
tutional cultures conditioning science production and the provision
of therapies. Our research categorises countries' regulatory dy-
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tory home-keeping with a country's ability to accumulate re-
sources, country size, healthcare demands, established traditions of
scientiﬁc governance, and economic and scientiﬁc ambitions. This
categorisation, in turn, embodies the differences between what are
regarded as large LMICs (China and India), small LMICs (Malaysia,
Vietnam), traditionally dominant confederates (EU and USA) and
advanced Asian countries (Japan and South Korea).
Regulatory diversity, we argued, has led to the emergence of
international organisations that promote dominant forms of ethical
review, scientiﬁc protocols and common scientiﬁc standards on
regional and international levels. This and dissatisfaction with na-
tional home-keeping policies has also led to the formation of
transnational scientiﬁc collaborations and networks that champion
and practise ‘alternative’ therapeutic practices and evaluation
methods. We argued that it is misleading to represent this friction
as a binary between bona ﬁde scientists and rogue scientists. In
general, the globalisation of stem cell science has created a greater
overall need to conﬁrm compliance with globally dominant stan-
dards and regulation. It is the diversity of ways in which countries
formulate and enforce these standards through their own regula-
tory boundary work, which is at stake.
In contrast with studies that frame translational stem cell sci-
ence in terms of bona ﬁde and rogue practices and Western (or
international) versus local, this study on national home-keeping
shows that ‘international regulation’ can be a ﬂag proudly carried
by privileged bearers, while masking extreme regulatory variation.
Although notions of hegemony are relevant here, they cannot
explain the difference between and within countries. Discourses on
the effects of neoliberalism turn LMICs into followers of ‘capital’,
rather than count them as important international actors, and tend
to discuss regulatory friction in terms of ethics and values. By
contrast, the notion of national home-keeping sheds light on reg-
ulatory agency, explaining the enabling and debilitating effects of
regulatory stalemates experienced in China and India; the gradual
regulatory reforms in the USA and the EU; the radical regulatory
changes in South Korea and Japan; and the ‘international’ regula-
tion adopted and violated by relative newcomers in the ﬁeld, such
as Malaysia, Thailand and Vietnam. In brief, the notion can help us
understand how some countries concurrently follow and resist
international regulation in the context of transnational collabora-
tions as well as why national governments deploy strategies that
appear to follow ‘international regulation’ to some extent, and at
the same time violate and infringe it.
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Appendix. Interviews (2012e2015)Table 3
Number of interviews per country and per category.
China India Japan Malaysia So
Company Managers 2 6 4 2 8
Medical Professionals 11 12 5 9
Patients 14 15 30 25
Regulators 1 6 3 2 5
Scientists 20 19 31 3 9
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